Abstract: (1791 Views)
Inflammatory rheumatic diseases, in addition to involvement of the joints and different systems, are associated with increased risk of morbidity and mortality. One of the most common causes of death in patients with these diseases is cardiovascular causes which can be due to the nature and pathophysiology of the disease, chronic inflammation, and the drugs used. Despite different pathogenesis and symptoms of rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, and gout, the presence of chronic inflammation is a common pathophysiological feature in these diseases. Metabolic syndrome is reported to be associated with some of these conditions. The study of metabolic syndrome in inflammatory rheumatic diseases is important from different perspectives, since it plays a role in development of cardiovascular disease and pro-inflammatory status and also influences the choice of treatment and related monitoring. Here, first, the importance of metabolic syndrome in rheumatic diseases in general is discussed, then each of the above diseases is evaluated separately. It seems that abdominal obesity in patients with rheumatoid arthritis and lupus, and hypertension and obesity in patients with psoriatic arthritis, and hypertriglyceridemia and hypertension in gout are important components of metabolic syndrome that require more care.